Search
Close this search box.

Abstract

Aim: Gaucher disease (GD) is caused by a deficiency of the lysosomal enzyme acid β-glucocerebrosidase. Recent metabolomic studies highlighted several new metabolites increased in the plasma of GD patients. We aimed to develop and validate a UPLC–MS/MS method allowing a relative quantitation of lyso-Gb1 and lyso-Gb1 analogs -28, -12, -2, +14, +16 and +18 Da in addition to sphingosylphosphorylcholine, N-palmitoyl-O-phosphocholine to study potential correlations with clinical manifestations. Methodology & results: Following solid-phase extraction, plasma samples were evaporated and resuspended in 100 μl of resuspension solution. Three microliter is injected into the UPLC–MS/MS for analysis. Conclusion: All biomarkers studied were increased in GD patients. Significant correlations were observed between specific analogs and hematological, and visceral complications, as well as overall disease severity.

Graphical abstract

Keywords:

  • biomarker
  • Gaucher disease
  • glucosylsphingosine
  • lyso-Gb1
  • lyso-Gb1 analogs
  • N-palmitoyl-O-phosphocholineserine
  • plasma
  • sphingosylphosphorylcholine
  • tandem mass spectrometry
Scroll to Top